Microbiome Global Market Report 2022: Rising Prevalence

DUBLIN, Aug. 31, 2022 (GLOBE NEWSWIRE) — Added the Microbiome Global Market Report 2022, Type, Application, Technology Offer.

The global microbiome market is expected to grow from US$0.27 billion in 2020 to US$0.37 billion in 2021 at a compound annual growth rate (CAGR) of 37%. The market is expected to reach $0.94 billion in 2025 at a CAGR of 26%.

The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel diseases (IBD) are a multifactorial and autoimmune group of infections consisting of two main entities such as ulcerative colitis (UC) and Crohn’s disease (CD).

Fecal microbiota transplantation (FMT) and probiotics have been discovered as potential applications in many immune-mediated diseases such as IBD to restore microbial balance. These microbial therapies have shown the potential to reduce both the dysbiotic state and the development of inflammatory mediators, thereby enabling remission, particularly in UC. In 2019, approximately 1.6 million people in the United States had untreatable inflammatory bowel disease (IBD), including Crohn’s disease or ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market.

The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of stool transplantation, a microbial therapy, can vary significantly depending on the method of administration used by users and the location where users receive it. Fecal microbiota transplant processes can cost anywhere from $600 to $1,000 depending on treatment method, area, insurance coverage, and other variables. Therefore, the high cost of microbial therapy is expected to hamper the growth of the microbiome market.

Increasing technological improvement is a major trend gaining popularity in the microbiome market. Large companies in the microbiome sector are focused on developing advanced technology solutions for microbiomes. For example, Seed, a new microbiome company, has introduced probiotic and prebiotic daily synbiotics for women and men. The Daily Synbiotic Seed is the first to adopt a microbial system strategy with strain-specific benefits that go beyond digestive health, such as cardiac safety, dermatological health, immune control, reproductive health, gut barrier integrity and oxidative stress.

Covered Markets:
1) By type: bacteria; different microbiome
2) By application: Inflammatory bowel disease; Diabetes; Multiple sclerosis; Rheumatoid arthritis; Other
3) By technology: genomics; proteomics; metabolism

Main topics covered:

1. Summary

2. Characteristics of Microbiome Market

3. Microbiome Market Trends and Strategies

4. Effects of COVID-19 on the microbiome

5. Microbiome Market Size and Growth

6. Microbiome Market Segmentation

7. Regional and country analysis of the microbiome market

8. Asia Pacific Microbiome Market

9. Microbiome Market in China

10. Indian Microbiome Market

11. Japan Microbiome Market

12th Australian Microbiome Market

13. Indonesia Microbiome Market

14. South Korea’s Microbiome Market

15. Microbiome Market in Western Europe

16th UK microbiome market

17. Germany microbiome market

18th France Microbiome Market

19. Eastern Europe Market for Microbiomes

20. Russia Microbiome Market

21. North America Microbiome Market

22nd US Microbiome Market

23. South America Microbiome Market

24. Brazil Microbiome Market

25th Middle East Microbiome Market

26th African Microbiome Market

27. Competitive Landscape and Company Profiles in the Microbiome Market

28. Microbiome pipeline analysis

29. Major mergers and acquisitions in the microbiome market

30. Future Outlook and Potential Analysis of Microbiome Market

31. Appendix

companies mentioned

  • MicroBiome Therapeutics LLC
  • Seres Therapeutics
  • Enteroma Life Sciences
  • Second Genome
  • Vedanta Biosciences Inc.
  • AbbVie Inc.
  • Rebiotix, Inc.
  • Ritter Pharma
  • LNC Therapeutics Inc.
  • ViThera Pharmaceuticals Inc.
  • 4D Pharma Plc.
  • Enthusiastic biotics
  • AOBiome
  • Immuron Ltd.
  • Ganeden
  • Pfizer Inc.
  • Bayer
  • Sigma Tau Pharmaceuticals
  • Assembly of Life Sciences
  • Admera Health
  • Synthetic Biologics
  • AgBiome
  • APC Microbiome Institute
  • ActoGeniX
  • azitra
  • Synlogic Inc.
  • Evelo Life Sciences
  • Maat Pharma

For more information about this report, visit

#Microbiome #Global #Market #Report #Rising #Prevalence Source

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *